Poclight Biotech

Founded in 2019 and based in Nanjing, China,Nanjing Poclight Biotechnology Co. , Ltd. , trading as Poclight Biotech, operates as a high-tech company that develops dry chemiluminescence diagnostic products based on resonance energy transfer technology. The company has 3,000 square meters of research, development and production sites, including 1,300 square meters of 10,000-level and 100,000-level GMP (good manufacturing practice) workshops, and has mastered the self-developed chemiluminescence resonance energy transfer (CRET) technology.

As of the third quarter of 2023, the Company has obtained 66 NMPA registrations and 131 CE certifications. In November 2025, Poclight Biotech raised an undisclosed amount of Series B funding from returning investor Wenzhou Investment, with participation from other new investor Gaoxin Huichuang. The company's main business is research and development of chemiluminescence resonance energy transfer (CRET) technology, drug research and development, retail, medical device research, development, manufacturing, and sales. The company has developed dry chemiluminescence immunoassay products, freeze-dried micro-pellet reagent products, as well as medical diagnosis, pet diagnosis and other related products, which serve the fields of drug detection, food detection, animal husbandry monitoring, environmental monitoring and so on.

The company generates revenue by developing and selling of in vitro medical diagnostic products such as dry chemiluminescent immunoassay products. The Series B funding raised in November 2025 will be used for technology research and development, product promotion, and market expansion.